GlassScriptPhysician profile
Michael Kooistra
NPI 1508864380
$3,322.77
in general payments reported to CMS, 2019-2025
26 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $13.65 · 2024: $1,542 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $540.72 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $517.01 | 2024-2025 | |
| Novo Nordisk INC | $369.81 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $273.59 | 2024-2025 | |
| Lilly USA, LLC | $225.55 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.81 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $212.34 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $187.54 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.56 | 2019-2025 | Jardiance, Ofev |
| Lundbeck LLC | $114.50 | 2024-2025 | Rexulti |
| Pfizer INC. | $67.92 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $61.14 | 2019-2025 | |
| Abbott Laboratories | $55.24 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $54.23 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $40.50 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39.56 | 2024 | Xarelto, Spravato |
| Corcept Therapeutics | $36.78 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $30.94 | 2024-2025 | Voquezna |
| Amgen INC. | $29.75 | 2024-2025 | Otezla, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $27.68 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $20.86 | 2024 | Eliquis |
| Corium, LLC | $19.92 | 2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $19.54 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $17.48 | 2025 | Auvelity |
| Eisai INC. | $15.87 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kooistra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.